Home About us Contact | |||
Latter Pattern (latter + pattern)
Selected AbstractsPatterns of morbidity in late medieval England: a sample from Westminster AbbeyECONOMIC HISTORY REVIEW, Issue 2 2001Barbara Harver A comparison between secular hospitals and monastic infirmaries introduces a discussion of the duration and seasonality of the illnesses of the monks of Westminster in two periods: 1297/8 to 1354/5 and 1381/2 to 1416/17. A change in the duration of illnesses is related to change in the conventions of treatment after the Black Death of 1348/9. The resemblance between the seasonal pattern of morbidity in this sample and that of mortality among male adults in the early modern period is discussed. It is suggested that the latter pattern may extend into the late middle ages. [source] Recombinant human glucose-6-phosphate dehydrogenaseFEBS JOURNAL, Issue 14 2002Evidence for a rapid-equilibrium random-order mechanism Cloning and over-expression of human glucose 6-phosphate dehydrogenase (Glc6P dehydrogenase) has for the first time allowed a detailed kinetic study of a preparation that is genetically homogeneous and in which all the protein molecules are of identical age. The steady-state kinetics of the recombinant enzyme, studied by fluorimetric initial-rate measurements, gave converging linear Lineweaver,Burk plots as expected for a ternary-complex mechanism. Patterns of product and dead-end inhibition indicated that the enzyme can bind NADP+ and Glc6P separately to form binary complexes, suggesting a random-order mechanism. The Kd value for the binding of NADP+ measured by titration of protein fluorescence is 8.0 µm, close to the value of 6.8 µm calculated from the kinetic data on the assumption of a rapid-equilibrium random-order mechanism. Strong evidence for this mechanism and against either of the compulsory-order possibilities is provided by repeating the kinetic analysis with each of the natural substrates replaced in turn by structural analogues. A full kinetic analysis was carried out with deaminoNADP+ and with deoxyglucose 6-phosphate as the alternative substrates. In each case the calculated dissociation constant upon switching a substrate in a random-order mechanism (e.g. that for NADP+ upon changing the sugar phosphate) was indeed constant within experimental error as expected. The calculated rate constants for binding of the leading substrate in a compulsory-order mechanism, however, did not remain constant when the putative second substrate was changed. Previous workers, using enzyme from pooled blood, have variously proposed either compulsory-order or random-order mechanisms. Our study appears to provide unambiguous evidence for the latter pattern of substrate binding. [source] Immunohistochemical profile of ephrin A4 expression in human osteosarcomaAPMIS, Issue 4 2009ASMAA GABER ABDOU Ephrin receptors and ephrin ligands constitute one of the largest groups of tyrosine kinases. The division of ephrin receptors into type A or type B is determined by their ligand-binding specificities. Ephrin A4 as a ligand has a broad capacity to bind and stimulate different subtypes of ephrin A receptors. Little is known about the role of ephrins generally and ephrin A4 particularly in osteosarcoma. Ephrin A4 was immunohistochemically assessed on archival material from 46 primary osteosarcoma cases, 10 metastatic pulmonary lesions and 20 normal control bone specimens. Ephrin A4 was expressed in 100% of normal bone specimens, in 84.4% of primary osteosarcoma cases and in all metastatic pulmonary lesions. Cytoplasmic and nucleocytoplasmic patterns of ephrin A4 immunoreactivity were observed, with the predominance of the latter pattern in normal bone (100%), and in 43.5% of primary osteosarcoma cases, which showed a higher intensity of expression compared with normal bone (p<0.05). The cytoplasmic pattern is the only staining pattern seen in metastatic cases, which may suggest its role in enhancement of invasion and metastasis. The differences in the distribution of the two patterns of ephrin A4 may indicate a different biological activity of this molecule depending on its localization. The nuclear localization of ephrin A4 requires further investigation to clarify the mechanism and the significance of the nuclear trafficking of ephrin A4. [source] Longitudinal changes in lung function and somatic growth in children with sickle cell disease,PEDIATRIC PULMONOLOGY, Issue 6 2007Anastassios C. Koumbourlis MD Abstract Background We studied the changes in the patterns of lung function and somatic growth over time in children and adolescents (10.6,±,3.5 years at first test) with hemoglobin SS (Hb-SS) sickle cell disease (SCD). Methods Lung function and somatic growth were measured twice with an interval of 42.3,±,23.3 months in 45 children (25 females and 20 males) with Hb-SS SCD. Results The lung volumes slightly decreased but remained borderline normal in both tests. All spirometric indices were within the normal range but significantly decreased (P,<,0.001) at the time of the second test indicating development of lower airway obstruction (forced expiratory volume in the first second (FEV1): 87,±,21 vs. 80,±,15; FEV1/forced vital capacity (FVC): 89,±,7 vs. 85,±,6; FEF25,75: 89,±,32 vs. 76,±,24). "Normal" pattern of lung function was initially found in 56% of the patients, but in only 29% in the second test. In contrast, those with "obstructive" pattern increased from 22 to 44%, and those with "restrictive" pattern from 22 to 27%. There was no association between history of asthma and pattern of lung function. "Normal" Body Mass Index (BMI) was found in 64% of the patients, whereas 13% had "High" BMI and 22% "Low" BMI. The two latter patterns were associated with abnormal lung function but only patients with normal BMI showed actual decline overtime. Conclusion SCD is characterized by a predominantly obstructive pattern of lung function that increases in prevalence over time. There was no apparent causal relationship between the pattern of somatic growth and the pattern of lung function. Pediatr Pulmonol. 2007; 42:483,488. © 2007 Wiley-Liss, Inc. [source] |